Next Phase Newsletter

The corporate venture capital arm of a medical real estate firm is currently seeking to invest in stage medical device companies with at least one product on the market and in need of funding to grow sales and broaden their product offering. The firm seeks to allocate $250K to $2M (in equity or mezzanine) per company. The firm invests in companies that are based in the US and is currently seeking the final investment for its fund. 

The firm seeks to invest in medical devices that provide solutions to unmet orthopedic, neurosurgical, and gastroenterology problems. The firm is focus on improving patient outcomes with reducing delivery costs. The firm prefers Class I and II devices that are nearing or have regulatory approval. The company must have at least one product on the market to be considered.

The firm looks to act as a strategic partner following investment offering management expertise in addition to capital.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm based in the Western United State is currently investing out of its 2^nd million dollar fund. The firm makes primarily equity investments ranging from $50,000 to $5 million over the lifetime of the investment. The firm prefers to invest in companies located in United States although they are also open to review internationally based opportunities and are currently working with a few companies in Israel. The firm plans to make approximately 2 new investments over the next 6-9 months.

The firm is looking for seed and venture stage medical and diagnostic device companies. In these areas the firm is most interested in single use devices capable of delivering a therapy, and in indications such as cancer, cardiovascular and neurological diseases, orthopedic problems, respiratory conditions, and gastrointestinal disorders. While this is the firms primary focus, they remain open minded to other types of devices and indications as well.

The firm looks for professionalism in a firms management teams and is willing to work with firms that do not yet have a complete management team in place. The firm does not always look to take a board seat into companies however they firm does look to add value by developing strategic corporate partnerships in Japan when appropriate.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm based in the Western United States is looking to invests in growth and expansion-stage technology and life science companies. The firm is currently investing from its inaugural fund and expects to close its second fund ($50M target) by the end of 2014. The firm prefers to make growth stage investments in Series C and D rounds, typically co-investing with other institutional investors. The investment size is variable depending on the company’s market capitalization. The firm focuses on companies that are located in regions underserved by venture capital such and the firm is actively seeking new investment opportunities.

In the life sciences the firm seeks to invest in therapeutics, medical devices, and diagnostics. The firm is opportunistic in terms of subsectors and indications. The firm seeks therapeutics that are at least in Phase III and medical devices that are very close to or with FDA approval. The firm historically invested in vitro diagnostic tests and medical imaging.

The firm generally co-invests with other top tier institutional investors and seeks companies with a strong and experienced management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital/incubation firm supports about 5 new early-stage life science companies per year, and provides two years of funding in return for equity.  Funding is only available to Israel-based companies; in cases where entrepreneurs based outside Israel would like to establish a company in Israel, an Israeli CEO/project manager is recruited by the firm.

The firm incubates medical device companies, and focuses on very early-stage ventures, including devices at or before the patent application stage; in such cases, the firm will help the innovator form a company and a management team.  The firm focuses on minimally invasive devices, and has experience of investing in cardiovascular devices, ophthalmology, orthopedic devices, laproscopic devices, and many other fields.  The firm is open to investing in any indication area.

The firm invests in companies targeting unmet medical needs with large markets, and seeks to invest in good management teams.  The firm prefers to invest in ventures that require $5m or less of R&D spending to reach the market.  As the the program provides funding for 2 years, the firm also helps its portfolio companies find additional funding to support future development.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A global private equity firm is looking to make direct equity investments into life science companies ranging from $5-25m, primarily in the USA and Europe, with the potential to invest in other areas if the right syndication opportunities are available.  The firm typically makes 10 new direct investments per year across a diverse range of sectors, including healthcare IT, therapeutics and medical devices.  The firm leads or co-leads financing rounds in about 60% of cases and takes a board seat in these instances, but on other occasions may syndicate with other investors and not take a board seat.

The firm prefers to invest in medical devices and therapeutics with the potential to become the standard of care in a large clinical area with unmet needs.  Focus indications include oncology, immunology, cardiology, diabetes, neurology, infectious diseases, respiratory disorders, pain management and psychiatry.  The firm prefers to invest in the later clinical stages (Phase II + III), but will consider opportunistic investments in earlier stage opportunities if the firm sees the potential for outsized risk-adjusted returns due to a market dislocation.

The firm also invests in healthcare IT companies that have a product already on the market and have attained revenue and customer adoption.  These investments are in a variety of market segments, including enterprise software, clinical management software, connected devices/equipment and direct-to-consumer products.

In the therapeutic and medical device sectors, the firm seeks to invest in companies with unique intellectual property and with strong investor syndicates who can fund late-stage clinical trials to completion.  In the healthcare IT sector, the firm prefers to invest in companies with at least $5m in revenue and strong, experienced management teams.  The firm performs thorough due diligence, looking at factors such as historical performance, size of market opportunity, revenue per customer and customer stickiness in addition to vetting the product itself and the management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The corporate venture capital arm of a large pharmaceutical company is currently looking to make equity investments into early stage life science companies. The firm has the ability to allocate up to $10 million dollars per company, generally in milestone driven tranches. The firm is able to invest in companies from around the globe and is actively seeking new investment opportunities.

The firm is looking for early stage companies working with therapeutics and companion diagnostics. The firm is open to review both small molecules and biologics as well as companies working with single assets or platform technologies. The firm seeks to invest in indication areas including Immunology, Oncology, Immunoncology, MS, and Fertility. The firm generally looks for companies with assets that are pre-clinical or in Phase I of clinical trials.

The firm is looking for privately held companies with experienced management teams. The firm looks to take an active role following investing generally taking at least a board seat. The firm is willing to both lead rounds and co-invest as a member of a syndicate.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm based in the Western United State is currently investing out of its 2^nd fund. The firm makes primarily equity investments ranging from $50,000 to $5 million over the lifetime of the investment. The firm prefers to invest in companies located in United States although they are also open to review internationally based opportunities and are currently working with a few companies in Israel. The firm plans to make approximately 2 new investments over the next 6-9 months.

The firm is looking for seed and venture stage medical and diagnostic device companies. In these areas the firm is most interested in single use devices capable of delivering a therapy, and in indications such as cancer, cardiovascular and neurological diseases, orthopedic problems, respiratory conditions, and gastrointestinal disorders. While this is the firms primary focus, they remain open minded to other types of devices and indications as well.

The firm looks for professionalism in a firms management teams and is willing to work with firms that do not yet have a complete management team in place. The firm does not always look to take a board seat into companies however they firm does look to add value by developing strategic corporate partnerships in Japan when appropriate.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com